Drug eluting stents and beyond.

Area of Science:

• Cardiovascular Medicine
• Biomaterials Science
• Pharmacology

Background:

• Atherosclerosis management involves various treatments, with stent thrombosis and restenosis being critical concerns.
• The development of novel stents, particularly drug-eluting stents (DES), necessitates a review of their quality control and drug delivery mechanisms.

Purpose of the Study:

• To elucidate the mechanism of late stent thrombosis and differentiate it from restenosis.
• To summarize FDA advisory notes on atherosclerosis treatment usage.
• To systematically review advancements in stent technology, including drug delivery, coatings, and novel concepts.

Main Methods:

• Literature review of recent developments in stent technology and drug delivery.
• Evaluation of upcoming drugs and biocompatible coatings for stent applications.
• Analysis of emerging drug-eluting stent (DES) technologies.

Main Results:

• Discussion of late stent thrombosis mechanisms and its distinction from restenosis.
• Summary of FDA recommendations for atherosclerosis treatment protocols.
• Overview of novelties in stent design, drug elution, and biocompatible coatings.
• Update on promising drug-eluting stents: Medtronic's Endeavor, Abbott's Xience, and Conor Medsystem's CoStar.

Conclusions:

• Continuous innovation in stent technology requires rigorous quality control and optimized drug delivery strategies.
• Understanding late stent thrombosis is crucial for improving patient outcomes in atherosclerosis treatment.
• Emerging drug-eluting stents show promise for enhanced therapeutic efficacy.